Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
type: MedicalStudy
description: A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2000-08
end date: 2007-02
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00193193
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: SCRI Development Innovations, LLC
study subject: Prostate Cancer
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Prostate Cancer

AI Analytics
type: Organization